Patents by Inventor Chudi Obioma NDUBAKU

Chudi Obioma NDUBAKU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20220211815
    Abstract: The present disclosure relates to a pharmaceutical composition comprising a STING agonist molecule in combination with an IL-15/IL-15Ra complex. The present combination can be administered independently or separately, in a quantity which is therapeutically effective for the treatment of cancer. Also provided is the use of such a combination for the manufacture of a medicament; the use of such a combination as a medicine; a kit of parts comprising such a combination; and a method of treatment of such a combination.
    Type: Application
    Filed: February 1, 2019
    Publication date: July 7, 2022
    Inventors: Nadja KOPP, Justin LEONG, Jeffrey MCKENNA, Chudi Obioma NDUBAKU, Maria PINZON-ORTIZ, Xianhui RONG, Ryan SULLIVAN
  • Locked nucleic acid cyclic dinucleotide compounds and uses thereof
    Patent number: 11098077
    Abstract: The present invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the LNA-CDNs of the present invention are provided in the form of a composition comprising one or more cyclic dinucleotides that induce human STING-dependent type I interferon production, wherein the cyclic dinucleotides present in the composition have at least one 2?, 4? locked nucleic acids within the cyclic dinucleotide.
    Type: Grant
    Filed: July 1, 2017
    Date of Patent: August 24, 2021
    Assignees: CHINOOK THERAPEUTICS, INC., NOVARTIS AG
    Inventors: David Braun Kanne, Chudi Obioma Ndubaku, Jacob Robert Bruml, Thanh Ngoc Lan Le, Jeffrey McKenna, George Scott Tria, Stephen Canham
  • Triazine Compounds and Uses Thereof
    Publication number: 20210246122
    Abstract: The present invention relates to triazine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: June 14, 2019
    Publication date: August 12, 2021
    Applicant: Aduro Biotech, Inc.
    Inventors: George Edwin Katibah, Jung Yun Kim, Chudi Obioma Ndubaku, Meiliana Tjandra, Tucker Curran Roberts
  • Bis 2?-5?-RR-(3?F-A)(3?F-A) cyclic dinucleotide compound and uses thereof
    Patent number: 10975114
    Abstract: The present invention provides the cyclic dinucleotide compound 2?2?-RR-(3?F-A)(3?F-A) as a highly active immune stimulator that activates DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes), and compositions and uses thereof.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: April 13, 2021
    Assignees: CHINOOK THERAPEUTICS, INC., NOVARTIS AG
    Inventors: Justin Leong, Chudi Obioma Ndubaku, Jeffrey McKenna
  • Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
    Patent number: 10906930
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?- or 3?-mono-fluoro substituted, or 2?3?-di-fluoro substituted mixed linkage 2?,5?-3?,5? CDNs.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: February 2, 2021
    Assignees: CHINOOK THERAPEUTICS, INC., NOVARTIS AG
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr., Jeffrey McKenna, Stephen M. Canham, Chudi Obioma Ndubaku
  • Pyrazolopyrimidinone compounds and uses thereof
    Patent number: 10738056
    Abstract: The present invention relates to pyrazolopyrimidinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: August 11, 2020
    Assignee: Aduro BioTech Inc.
    Inventors: Chudi Obioma Ndubaku, George Edwin Katibah, Tucker Curran Roberts, Leonard Sung, Stephane Ciblat, Franck Raeppel, Vu Linh Ly, Yeeman K. Ramtohul, Taras Rybak, Mariam Zaky, Laura Gillard, Hossein Ismaili
  • BIS 2'-5'-RR-(3'F-A)(3'F-A) CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF
    Publication number: 20200199169
    Abstract: The present invention provides the cyclic dinucleotide compound 2?2?-RR-(3?F-A)(3?F-A) as a highly active immune stimulator that activates DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes), and compositions and uses thereof.
    Type: Application
    Filed: April 26, 2018
    Publication date: June 25, 2020
    Inventors: Justin LEONG, Chudi Obioma NDUBAKU, Jeffrey MCKENNA
  • IMIDAZOPYRIDAZINONE COMPOUNDS AND USES THEREOF
    Publication number: 20200181153
    Abstract: The present invention relates to imidazopyridazinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: December 10, 2019
    Publication date: June 11, 2020
    Inventors: Chudi Obioma Ndubaku, Tucker Curran Roberts, Thomas Johnson, Stephane Ciblat, Yeeman K. Ramtohul, Bernadette K. Latimer
  • LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF
    Publication number: 20190185511
    Abstract: The present invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the LNA-CDNs of the present invention are provided in the form of a composition comprising one or more cyclic dinucleotides that induce human STING-dependent type I interferon production, wherein the cyclic dinucleotides present in the composition have at least one 2?, 4? locked nucleic acids within the cyclic dinucleotide.
    Type: Application
    Filed: July 1, 2017
    Publication date: June 20, 2019
    Applicants: ADURO BIOTECH, INC., NOVARTIS AG
    Inventors: David Braun KANNE, Chudi Obioma NDUBAKU, Jacob Robert BRUML, Thanh Ngoc Lan LE, Jeffrey MCKENNA, George Scott TRIA, Stephen CANHAM
  • PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF
    Publication number: 20190119285
    Abstract: The present invention relates to pyrazolopyrimidinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: September 14, 2018
    Publication date: April 25, 2019
    Inventors: Chudi Obioma NDUBAKU, George Edwin KATIBAH, Tucker Curran ROBERTS, Leonard SUNG, Stephane CIBLAT, Franck RAEPPEL, Vu Linh LY, Yeeman K. RAMTOHUL, Taras RYBAK, Mariam ZAKY, Laura GILLARD, Hossein ISMAILI
  • COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE"-DEPENDENT SIGNALLING
    Publication number: 20190062365
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?- or 3?-mono-fluoro substituted, or 2?3?-di-fluoro substituted mixed linkage 2?,5?-3?,5? CDNs.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 28, 2019
    Applicants: ADURO BIOTECH, INC., NOVARTIS AG
    Inventors: George Edwin KATIBAH, David KANNE, Leonard SUNG, Kelsey GAUTHIER, Laura Hix GLICKMAN, Justin LEONG, Sarah M. McWHIRTER, Thomas W. DUBENSKY, Jr., Jeffrey McKENNA, Stephen M. CANHAM, Chudi Obioma NDUBAKU